| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| S3 |
|
C37H61N11O14S2 |
948.08 |
H2N-CSISSLTHC-OH |
H2N-Cys-Ser-Ile-Ser-Ser-Leu-Thr-His-Cys-OH |
9 |
NKAa1-targeting peptide |
|
| TH19P01 |
|
C85H138N26O25 |
1924.16 |
Ac-GVRAKAGVRN-Nle-FKSESY-OH |
Ac-Gly-Val-Arg-Ala-Lys-Ala-Gly-Val-Arg-Asn-Nle-Phe-Lys-Ser-Glu-Ser-Tyr-OH |
17 |
SORT1 receptor–targeting peptide |
|
| KTLLPTP |
|
C36H64N8O10 |
768.94 |
H2N-KTLLPTP-OH |
H2N-Lys-Thr-Leu-Leu-Pro-Thr-Pro-OH |
7 |
Pancreatic cancer–targeting peptide |
|
| L-VAP |
|
C30H53N11O11 |
743.81 |
H2N-sntrvap-OH |
H2N-DSer-DAsn-DThr-DArg-DVal-DAla-DPro-OH |
7 |
GRP78-targeting peptide |
|
| ACTTPHAWLC |
|
C50H74N14O14S2 |
1159.34 |
H2N-ACTTPHAWLCG-OH |
H2N-Ala-Cys-Thr-Thr-Pro-His-Ala-Trp-Leu-Cys-Gly-OH |
11 |
Nose-to-brain–targeting peptide |
|
| PepTGN |
|
C57H85N19O17 |
1308.4 |
H2N-TGNYKALHPHNG-OH |
H2N-Thr-Gly-Asn-Tyr-Lys-Ala-Leu-His-Pro-His-Asn-Gly-OH |
12 |
Brain-targeting peptide |
|
| TCP-1 |
|
C41H57N11O13S2 |
976.09 |
H2N-CTPSPFSHC-OH |
H2N-Cys-Thr-Pro-Ser-Pro-Phe-Ser-His-Cys-OH |
9 |
Orthotopic colorectal cancer vasculature–targeting peptide |
|
| IPQILSI(IPQ*) |
|
C37H66N8O10 |
782.97 |
H2N–IPQILSI–OH |
H2N–Ile–Pro–Gln–Ile–Leu–Ser–Ile–OH |
7 |
LGR5-targeting peptide |
|
| P1 |
|
C85H117N27O21 |
1853.01 |
H2N-NPNWGRSWYNQRFK-OH |
H2N-Asn-Pro-Asn-Trp-Gly-Arg-Ser-Trp-Tyr-Asn-Gln-Arg-Phe-Lys-OH |
14 |
HER2-targeting peptide |
|
| (KKEEE)3K |
|
C87H149N23O35 |
2077.25 |
H2N-KKEEEKKEEEKKEEEK-OH |
H2N-Lys-Lys-Glu-Glu-Glu-Lys-Lys-Glu-Glu-Glu-Lys-Lys-Glu-Glu-Glu-Lys-OH |
16 |
Proximal tubule cell–targeting peptide |
|
| P144 |
|
C65H103N17O22S2 |
1538.74 |
H2N-TSLDASIWAMMQNA-OH |
H2N-Thr-Ser-Leu-Asp-Ala-Ser-Ile-Trp-Ala-Met-Met-Gln-Asn-Ala-OH |
14 |
TGF-β–targeting peptide |
|
| Caffeic acid–pYEEIE |
507471-72-9 |
C39H50N5O19P |
923.81 |
pYEEIE |
pTyr–Glu–Glu–Ile–Glu |
5 |
Non-phosphorylated peptide inhibitors |
|
| PBP |
|
C40H57N9O16 |
919.93 |
H2N-DAEWVDVS-OH |
H2N-Asp-Ala-Glu-Trp-Val-Asp-Val-Ser-OH |
8 |
P-selectin–targeting peptide |
|
| CCBP1 |
|
C33H55N13O9S1 |
809.94 |
H2N-HAMRAQP-OH |
H2N-His-Ala-Met-Arg-Ala-Gln-Pro-OH |
7 |
Colon adenocarcinoma cell–targeting peptide |
|
| HCSP4 |
|
C60H85N17O19 |
1348.42 |
H2N-SLDSTHTHAPWP-OH |
H2N-Ser-Leu-Asp-Ser-Thr-His-Thr-His-Ala-Pro-Trp-Pro-OH |
12 |
Hepatocellular carcinoma–targeting peptide |
|
| RMS-II |
|
C52H93N21O15S3 |
1348.62 |
H2N-CMGNKRSAKRPC-OH |
H2N-Cys-Met-Gly-Asn-Lys-Arg-Ser-Ala-Lys-Arg-Pro-Cys-OH |
12 |
Rhabdomyosarcoma (RMS)–targeting peptide |
|
| CTGNQAAFC |
|
C36H55N11O13S2 |
914.02 |
H2N-CTGNQAAFC-OH |
H2N-Cys-Thr-Gly-Asn-Gln-Ala-Ala-Phe-Cys-OH |
9 |
SK-BR-3 cell–targeting peptid |
|
| tLyP-1 |
1354801-55-0 |
C31H59N15O10S1 |
833.96 |
H2N-CGNKRTR-OH |
H2N-Cys-Gly-Asn-Lys-Arg-Thr-Arg-OH |
7 |
|
|
| dTIT7 |
|
C39H60N8O11S1 |
849.01 |
H2N–titwptm–OH |
H2N–DThr–DIle–DThr–DTrp–DPro–DThr–DMet–OH |
7 |
ANXA1-targeting peptide |
|
| IPLPPPSRPFFKY |
|
C79H116N18O15 |
1557.88 |
H2N-IPLPPPSRPFFKY-CONH2 |
H2N-Ile-Pro-Leu-Pro-Pro-Pro-Ser-Arg-Pro-Phe-Phe-Lys-Tyr-CONH2 |
13 |
PDGFR-β–targeting peptide |
|
